NO20052683D0 - Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem - Google Patents

Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem

Info

Publication number
NO20052683D0
NO20052683D0 NO20052683A NO20052683A NO20052683D0 NO 20052683 D0 NO20052683 D0 NO 20052683D0 NO 20052683 A NO20052683 A NO 20052683A NO 20052683 A NO20052683 A NO 20052683A NO 20052683 D0 NO20052683 D0 NO 20052683D0
Authority
NO
Norway
Prior art keywords
processes
preparation
new
pharmaceutical compositions
compositions containing
Prior art date
Application number
NO20052683A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052683L (no
Inventor
Sylvain Rault
Jean-Charles Lancelot
Pierre Renard
Daniel-Henri Caignard
Marina Kopp
Buno Pfeiffer
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of NO20052683D0 publication Critical patent/NO20052683D0/no
Publication of NO20052683L publication Critical patent/NO20052683L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20052683A 2002-11-05 2005-06-03 Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem NO20052683L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0213804A FR2846657B1 (fr) 2002-11-05 2002-11-05 Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/FR2003/003274 WO2004043956A1 (fr) 2002-11-05 2003-11-04 Composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
NO20052683D0 true NO20052683D0 (no) 2005-06-03
NO20052683L NO20052683L (no) 2005-06-03

Family

ID=32104442

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052683A NO20052683L (no) 2002-11-05 2005-06-03 Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem

Country Status (28)

Country Link
US (1) US7361662B2 (uk)
EP (1) EP1560826B1 (uk)
JP (1) JP2006512317A (uk)
KR (1) KR100717489B1 (uk)
CN (1) CN1330650C (uk)
AR (1) AR041883A1 (uk)
AT (1) ATE323092T1 (uk)
AU (1) AU2003292320B2 (uk)
BR (1) BR0315801A (uk)
CA (1) CA2503995A1 (uk)
CY (1) CY1105047T1 (uk)
DE (1) DE60304599T2 (uk)
DK (1) DK1560826T3 (uk)
EA (1) EA009043B1 (uk)
ES (1) ES2261978T3 (uk)
FR (1) FR2846657B1 (uk)
GE (1) GEP20084376B (uk)
HK (1) HK1081965A1 (uk)
MA (1) MA27410A1 (uk)
MX (1) MXPA05004789A (uk)
MY (1) MY140164A (uk)
NO (1) NO20052683L (uk)
NZ (1) NZ539598A (uk)
PL (1) PL376399A1 (uk)
PT (1) PT1560826E (uk)
UA (1) UA80578C2 (uk)
WO (1) WO2004043956A1 (uk)
ZA (1) ZA200503233B (uk)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101547922B (zh) * 2006-10-04 2012-06-20 辉瑞产品公司 作为钙受体拮抗剂的吡啶并[4,3-d]嘧啶-4(3H)-酮衍生物
CN101531638B (zh) * 2008-03-13 2011-12-28 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
CN101619063B (zh) * 2009-06-02 2011-08-10 华中师范大学 具有抗肿瘤活性的3,7,8-多取代吡啶并[4,3-d]嘧啶衍生物及制备
US8981087B2 (en) 2009-07-29 2015-03-17 Karus Therapeutics Limited Benzo [E] [1,3] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors
JP5746172B2 (ja) 2009-08-20 2015-07-08 カルス セラピューティクス リミテッド ホスホイノシチド３−キナーゼ阻害剤としての三環式複素環化合物
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
JP6535430B2 (ja) 2012-09-28 2019-06-26 イグニタ、インク． 非定型プロテインキナーゼｃのアザキナゾリン阻害薬
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
CN107001358A (zh) 2014-10-29 2017-08-01 东亚St株式会社 调节组蛋白赖氨酸脱甲基酶(kdm)催化活性的新型吡啶并嘧啶酮化合物
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
US20170057955A1 (en) * 2015-08-26 2017-03-02 Dong-A Socio Holdings Co., Ltd. Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs)
CN105616420A (zh) * 2016-01-16 2016-06-01 赵国良 一种降血脂的药物组合物
JP7268049B2 (ja) 2018-03-08 2023-05-02 インサイト・コーポレイション ＰＩ３Ｋ－γ阻害剤としてのアミノピラジンジオール化合物
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
JP2023502476A (ja) * 2019-11-22 2023-01-24 センダ バイオサイエンシーズ， インコーポレイテッド Ａｈｒアンタゴニストとしてのピリドピリミジノン誘導体
WO2024008722A2 (en) * 2022-07-04 2024-01-11 Muna Therapeutics Aps Trem2 modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348310B1 (en) * 1994-03-04 2002-02-19 Promega Corporation Quantitation of individual protein kinase activity
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
ZA9756B (en) * 1996-01-16 1997-07-17 Warner Lambert Co Process for preparing 4,6-disubstituted pyrido[3,4-d]-pyrimidines
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
ATE232863T1 (de) * 1996-08-06 2003-03-15 Pfizer Substituierte pyrido- oder pyrimidogruppen enthaltende 6,6- oder 6,7-bicyclische derivate
US6962922B2 (en) * 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
AUPS019702A0 (en) * 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds

Also Published As

Publication number Publication date
FR2846657A1 (fr) 2004-05-07
KR100717489B1 (ko) 2007-05-14
GEP20084376B (en) 2008-05-27
DK1560826T3 (da) 2006-08-14
WO2004043956A8 (fr) 2005-06-09
AR041883A1 (es) 2005-06-01
DE60304599D1 (de) 2006-05-24
KR20050087792A (ko) 2005-08-31
NZ539598A (en) 2006-11-30
ATE323092T1 (de) 2006-04-15
CY1105047T1 (el) 2009-11-04
CN1330650C (zh) 2007-08-08
WO2004043956A1 (fr) 2004-05-27
US7361662B2 (en) 2008-04-22
DE60304599T2 (de) 2007-05-16
EP1560826B1 (fr) 2006-04-12
ES2261978T3 (es) 2006-11-16
AU2003292320B2 (en) 2009-03-12
PT1560826E (pt) 2006-07-31
EP1560826A1 (fr) 2005-08-10
HK1081965A1 (en) 2006-05-26
MA27410A1 (fr) 2005-06-01
FR2846657B1 (fr) 2004-12-24
MXPA05004789A (es) 2005-07-22
NO20052683L (no) 2005-06-03
JP2006512317A (ja) 2006-04-13
US20050288311A1 (en) 2005-12-29
CN1711260A (zh) 2005-12-21
EA200500690A1 (ru) 2005-10-27
BR0315801A (pt) 2005-09-20
PL376399A1 (en) 2005-12-27
MY140164A (en) 2009-11-30
AU2003292320A1 (en) 2004-06-03
EA009043B1 (ru) 2007-10-26
CA2503995A1 (fr) 2004-05-27
UA80578C2 (en) 2007-10-10
ZA200503233B (en) 2006-06-28

Similar Documents

Publication Publication Date Title
NO20052683D0 (no) Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20054329D0 (no) Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
NO20054876D0 (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
NO20042805L (no) Nye forbindelser og deres anvendelse innen medisin, fremgangsmate for deres fremstilling og farmaoytiske sammensetninger som inneholder dem
NO20023643L (no) Forbindelser som har antitumoraktivitet, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger som inneholderdem
NO20055167D0 (no) Nye benzotiadiazinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20055835D0 (no) Cykliske aminderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20010522D0 (no) Nye piperidin-4-sulfonamidforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem
NO20052414L (no) Nye pyrrolidin- og tiazolidinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20043188L (no) Nye heterocykliske oksimforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20052598D0 (no) Nye 2,3-dihydro-4(1H)-pyridonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem.
NO20031219D0 (no) Nye forbindelser avledet fra kinazolin, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger inneholdende dem
NO20010305D0 (no) Nye benzensulfonamidforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem
NO20031643D0 (no) Nye aminotriazolonforbindelser, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger inneholdende dem
NO20034614L (no) Nye [3,4-a:3,4-c]karbazolforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20041313L (no) Nye isokinolinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20042978L (no) Nye benzotiazin- og benzotiadiazinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20050391D0 (no) Nye fluorinerte benzotiadiazinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20021330D0 (no) Nye indenoindolonforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem
NO20043910L (no) Nye aminosyreforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20042422L (no) Nye benzotiazin- og benzotiadiazinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20052330D0 (no) Nye substituerte [1,4]benzodioksino[2,3]isoindolforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20043880L (no) Nye benzoindolinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20021198L (no) Nye isoindoloindolonforbindelser, fremgangsmate ved deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20035215D0 (no) Tricykliske dihydrokinolinforbindelser, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger inneholdende dem

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application